# Ubix Therapeutics

Source: https://onco.cc/companies/ubix-therapeutics/  
OnCo record `ubix-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Ubix Therapeutics is a Korean company making medicines that make cancer cells break down a target protein rather than just block it. Its lead drug destroys BTK, a protein that drives B-cell blood cancers, including forms resistant to current BTK inhibitors.

## Summary

Ubix Therapeutics, Inc., based in Songpa-gu, Seoul, develops targeted protein degraders it calls Degraducers. Its lead programme UBX-303-1 (registered as UBX-303061) degrades Bruton's tyrosine kinase (BTK) and, according to the company, showed antitumour activity in preclinical models with wild-type BTK and the C481S resistance mutation; UBX-106 and UBX-306 are undisclosed immuno-oncology programmes. In March 2026 the company withdrew its application for preliminary review of a KOSDAQ listing, saying it would reapply after clinical results and licensing progress. Its first registered cancer trial, NCT06590961, a phase 1a/1b dose-escalation and expansion study of UBX-303061 in relapsed or refractory B-cell malignancies at sites in the United States, Poland and Korea, was posted on ClinicalTrials.gov in September 2024.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Ubix Therapeutics, Inc.; 유빅스테라퓨틱스
- HQ: Seoul
- Type: biotech
- Website: https://ubixtrx.com/

## Notes

- Founding year and financing not stated on the pages read. The listing withdrawal is from a Korean-language headline on the company home page. The pipeline page names chronic lymphocytic leukaemia among intended indications; text was partly in Korean. Read on 29 October 2026.

## Sources

- Official website: https://ubixtrx.com/
- Pipeline: https://ubixtrx.com/pipeline
- ClinicalTrials.gov: phase 1 trial of UBX-303061 (NCT06590961): https://clinicaltrials.gov/study/NCT06590961

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [PROTACs & molecular glues (targeted protein degradation)](https://onco.cc/technologies/protac-degrader/)
- targets: [BTK (Bruton tyrosine kinase)](https://onco.cc/targets/btk/)

---
JSON: https://onco.cc/api/v1/entities/ubix-therapeutics.json